Overactive Bladder Syndrome: Evaluation and Management

Overactive bladder (OAB) syndrome is a chronic medical condition which has a major influence on the quality of life in a significant amount of the population. OAB affects performance of daily activities and has an estimated prevalence of 16.5%. Many sufferers do not seek medical help. Moreover, many family physicians and even gynecologists are not familiar with this issue. Usually patients suffer from OAB in advanced age. Nocturia is reported as the most bothersome symptom in the elderly population. The aim of our review was to discuss all aspects of this challenging disorder and suggest tools for assessment and management strategies. Practitioners can easily overlook urinary complains if they not directly queried. We would like to encourage practitioners to give more attention to this issue.

[1]  S. Aballéa,et al.  Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. , 2014, European urology.

[2]  C. Nardo,et al.  OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. , 2013, European urology.

[3]  G. Amarenco,et al.  Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. , 2013, European urology.

[4]  From Ora Staff Reports.  FDA approves Botox to treat overactive bladder , 2013 .

[5]  K. Burgio,et al.  Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. , 2012, The Journal of urology.

[6]  J. Corcos,et al.  Normal lower urinary tract assessment in women: I. Uroflowmetry and post-void residual, pad tests, and bladder diaries , 2012, International Urogynecology Journal.

[7]  P. Dasgupta,et al.  Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates. , 2012, European urology.

[8]  L. Cardozo,et al.  Antimuscarinic drugs to treat overactive bladder , 2012, BMJ : British Medical Journal.

[9]  M. Oefelein.  Safety and Tolerability Profiles of Anticholinergic Agents Used for the Treatment of Overactive Bladder , 2011, Drug safety.

[10]  K. Coyne,et al.  Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature , 2011, International journal of clinical practice.

[11]  J. Kowalski,et al.  A prospective observational study of the effects of treatment with extended-release tolterodine on health-related quality of life of patients suffering overactive bladder syndrome in Sweden , 2010, Scandinavian journal of urology and nephrology.

[12]  J. J. de la Rosette,et al.  The role of nocturia in the quality of life of men with lower urinary tract symptoms , 2010, BJU international.

[13]  W. Yoong,et al.  Tibial nerve stimulation for overactive bladder syndrome unresponsive to medical therapy , 2010, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[14]  S. Herschorn,et al.  Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head‐to‐head placebo‐controlled trial , 2010, BJU international.

[15]  K. Andersson.  Detrusor myocyte activity and afferent signaling , 2010, Neurourology and urodynamics.

[16]  R. Freeman,et al.  An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction , 2010, International Urogynecology Journal.

[17]  K. Coyne,et al.  The total economic burden of overactive bladder in the United States: a disease-specific approach. , 2009, The American journal of managed care.

[18]  Y. Homma,et al.  Clinical guidelines for overactive bladder , 2009, International journal of urology : official journal of the Japanese Urological Association.

[19]  Z. Gabriel,et al.  The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. , 2008, European urology.

[20]  B. Olshansky,et al.  Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-controlled, Double-blind, Crossover Study With Tolterodine and Darifenacin in Healthy Participants ≥50 Years , 2008, Journal of cardiovascular pharmacology and therapeutics.

[21]  P. Abrams,et al.  How should patients with an overactive bladder manipulate their fluid intake? , 2008, BJU international.

[22]  M. Elhilali,et al.  Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. , 2007, The Journal of urology.

[23]  O. Löfgren.  Re: Overactive bladder: a better understanding of pathophysiology, diagnosis and management. A. J. Wein and R. R. Rackley J Urol, suppl., 2006; 175: S5-S10. , 2007, The Journal of urology.

[24]  L. Cardozo,et al.  Management of overactive bladder syndrome , 2007, Postgraduate Medical Journal.

[25]  D. Newman,et al.  Overactive bladder: recognition requires vigilance for symptoms. , 2007, Cleveland Clinic journal of medicine.

[26]  C. Ramsay,et al.  Bowel dysfunction after transposition of intestinal segments into the urinary tract: 8-year prospective cohort study. , 2007, The Journal of urology.

[27]  A. Heintz,et al.  Association between urogenital symptoms and depression in community-dwelling women aged 20 to 70 years. , 2007, Urology.

[28]  J. Gums,et al.  Newer agents for the management of overactive bladder. , 2006, American family physician.

[29]  A. Te,et al.  Refractory overactive bladder in men: Update on novel therapies , 2006, Current urology reports.

[30]  G. P. Herbison,et al.  Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. , 2006, The Cochrane database of systematic reviews.

[31]  B. Schurch,et al.  Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. , 2006, The Journal of urology.

[32]  A. Wein,et al.  Overactive bladder: a better understanding of pathophysiology, diagnosis and management. , 2006, The Journal of urology.

[33]  A. Brading.  Spontaneous activity of lower urinary tract smooth muscles: correlation between ion channels and tissue function , 2006, The Journal of physiology.

[34]  Robyn Ijeoma Okpara-Kamanu.  Re: Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 2005;48:5-26. , 2005, European urology.

[35]  C. Chapple,et al.  A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. , 2005, European urology.

[36]  Z. Gabriel,et al.  The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. , 2005, European urology.

[37]  K. Andersson.  New pharmacologic targets for the treatment of the overactive bladder: an update. , 2004, Urology.

[38]  R. Dmochowski,et al.  Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. , 2003, Mayo Clinic proceedings.

[39]  W. Stewart,et al.  Prevalence and burden of overactive bladder in the United States , 2003, World Journal of Urology.

[40]  Two of the same , 2003, BMJ : British Medical Journal.

[41]  A. Shafik,et al.  Overactive bladder inhibition in response to pelvic floor muscle exercises , 2003, World Journal of Urology.

[42]  M. Borrie,et al.  Urinary retention in patients in a geriatric rehabilitation unit: prevalence, risk factors, and validity of bladder scan evaluation. , 2001, Rehabilitation nursing : the official journal of the Association of Rehabilitation Nurses.

[43]  MJ Drake,et al.  Model of peripheral autonomous modules and a myovesical plexus in normal and overactive bladder function , 2001, The Lancet.

[44]  P. Abrams,et al.  How widespread are the symptoms of an overactive bladder and how are they managed? A population‐based prevalence study , 2001, BJU international.

[45]  R. Dmochowski,et al.  Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. , 2001, Mayo Clinic proceedings.

[46]  A. Wein,et al.  Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. , 2001, Urology.

[47]  P. Goode,et al.  Combined Behavioral and Drug Therapy for Urge Incontinence in Older Women , 2000, Journal of the American Geriatrics Society.

[48]  Richard A. Schmidt,et al.  SACRAL NERVE STIMULATION FOR TREATMENT OF REFRACTORY URINARY URGE INCONTINENCE , 1999 .

[49]  W. C. Groat.  A neurologic basis for the overactive bladder , 1997 .

[50]  H. Kamphuisen,et al.  Subjective sleep characteristics of 1,485 males and females aged 50-93: effects of sex and age, and factors related to self-evaluated quality of sleep. , 1996, The journals of gerontology. Series A, Biological sciences and medical sciences.

[51]  W. Oosterlinck,et al.  Experience with augmentation cystoplasty. A review , 1995, Paraplegia.

[52]  J. Holm,et al.  [Augmentation ileo-cystoplasty in women with disabling urge incontinence]. , 1995, Ugeskrift for laeger.

[53]  C. West,et al.  Maximum and average urine flow rates in normal male and female populations--the Liverpool nomograms. , 1989, British journal of urology.

[54]  K. Ogbonnaya,et al.  Pathophysiology, Diagnosis, and Management , 2017 .

[55]  S. Lohsiriwat,et al.  Effect of caffeine on bladder function in patients with overactive bladder symptoms , 2011, Urology annals.

[56]  Magnus Fall,et al.  The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. , 2003, Urology.

[57]  M. Chancellor.  New frontiers in the treatment of overactive bladder and incontinence. , 2002, Reviews in urology.

[58]  D. Roth,et al.  Reliability assessment of the bladder diary for urinary incontinence in older women. , 2001, The journals of gerontology. Series A, Biological sciences and medical sciences.

[59]  R A Janknegt,et al.  Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral Nerve Stimulation Study Group. , 1999, The Journal of urology.

[60]  N. Kohli,et al.  Pharmacologic Causes of Female Incontinence , 1999, International Urogynecology Journal.

[61]  W. D. de Groat,et al.  A neurologic basis for the overactive bladder. , 1997, Urology.

[62]  P. Glue,et al.  Bmc Medical Research Methodology Open Access a Meta-analysis of the Placebo Response in Antimuscarinic Drug Trials for Overactive Bladder , 2022 .

[63]  C. Hampel,et al.  Actas Urológicas Españolas Eau Guidelines on Urinary Incontinence Palabras Clave , 2022 .